Sonrotoclax and Obinutuzumab for Treatment-Naïve CLL - Dr. Marc Hoffmann and Dr. Paul Hampel

Sonrotoclax plus obinutuzumab appears to be well-tolerated and produces deep responses in patients with treatment-naïve CLL / SLL. Dr. Marc Hoffmann from the University of Kansas Cancer Center and colleagues presented the results at the American Society for Hematology (ASH) Annual Meeting in 2025. Read the full article on CLL Society's website at: https://cllsociety.org/2026/04/sonrot... __________________________________________________________________________________________ CLL Society Website: https://cllsociety.org/ Facebook:   / cllsociety   Twitter:   / cllsociety   LinkedIn:   / cll-society